steven boyd, biotech stock review

Armistice Capital Master Fund Ltd., and Citius Pharma (CTXR).

April 2019 Offering On April 1, 2019, Citius entered into securities purchase agreements with institutional investors and accredited investors...
candida auris, citius pharma, biotech stock review

Citius Pharma’s (CTXR) Mino-Lok® Highly Efficacious in Rapidly Eradicating Candida auris.

CRANFORD, N.J., May 13, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug...

Latest article

Immunomedics, Biotech Stock Review

Biotech 5 Pack. 5 Biotech Stocks We Expect to Double in 2020.

Our First Newsletter of 2020, We Come out Swinging! Yes, you read it right. Five of our favorite...
Citius Pharmaceutical, CTXR, Biotech Stock Review

Citius Pharma (CTXR) Now Our #1 Ranked Idea for 2020.

Citius Pharmaceuticals (CTXR) is hands down one of the most exciting long-term opportunities we have come across since we first launched the...
Oramed, Biotech Stock REview

Oramed (ORMP) $5.24, Focused on Pill Form Insulin. Is China First?

New technology could revolutionize market of 500 million diabetes patients (i24 News).